Tadahiro Sato Selected Research

Yi-Gan San

1/2016	Yokukansan improves behavioral and psychological symptoms of dementia by suppressing dopaminergic function.
10/2013	Efficacy and tolerability of risperidone, yokukansan, and fluvoxamine for the treatment of behavioral and psychological symptoms of dementia: a blinded, randomized trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tadahiro Sato Research Topics

Disease

3	Dementia (Dementias) 01/2016 - 12/2006
3	Bipolar Disorder (Manic Depressive Psychosis) 01/2015 - 10/2012
2	Mania (Manias) 01/2015 - 01/2014
1	Substance Withdrawal Syndrome (Withdrawal Symptoms) 01/2017
1	Tobacco Use Disorder (Nicotine Dependence) 01/2017
1	Mood Disorders (Mood Disorder) 01/2014
1	Astrocytoma (Pilocytic Astrocytoma) 10/2012
1	Depressive Disorder (Melancholia) 01/2012
1	Alzheimer Disease (Alzheimer's Disease) 12/2006
1	Alcoholism (Alcohol Abuse) 01/2006

Drug/Important Bio-Agent (IBA)

3	Biomarkers (Surrogate Marker)IBA 01/2017 - 01/2014
3	Fluvoxamine (Luvox)FDA LinkGeneric 01/2016 - 12/2006
3	Brain-Derived Neurotrophic Factor (BDNF)IBA 01/2014 - 01/2012
2	Yi-Gan SanIBA 01/2016 - 10/2013
2	Risperidone (Risperdal Consta)FDA LinkGeneric 01/2016 - 10/2013
2	Norepinephrine (Noradrenaline)FDA LinkGeneric 01/2015 - 01/2014
2	MethoxyhydroxyphenylglycolIBA 01/2015 - 01/2014
1	Nicotine FDA Link 01/2017
1	LithiumIBA 10/2012
1	Valproic Acid (Depakote)FDA LinkGeneric 10/2012
1	Pharmaceutical PreparationsIBA 12/2006
1	mu Opioid Receptors (mu Opioid Receptor)IBA 01/2006

Therapy/Procedure

1	Therapeutics 10/2012